COLUMBUS, Ohio and FAYETTEVILLE, Ark., July 25,
2024 /PRNewswire/ -- Paradigm and Highlands Oncology
announce promising results from their ongoing collaboration,
demonstrating a 45% increase in the number of patients enrolled in
clinical trials. The achievement aligns with the objectives to
maximize the availability of clinical trials for all patients in
the region.
Highlands is a large, community oncology cancer center located
in the northwest Arkansas
corridor, which provides care not only to Arkansas, but to surrounding Oklahoma and Missouri.
"Northwest Arkansas is a
wonderful place to live, work and raise a family, however, there
are tremendous geographical barriers to participation in
university-based clinical research programs in the region," said J.
Thaddeus Beck, MD, FACP, Co-Founder
and Medical Director of Research at Highlands Oncology. "Highlands
is dedicated to providing the highest quality of cancer care as
well as fulfilling the need for patient access to clinical trials
in our community."
"Access to cancer care varies dramatically depending on where
you live," said Kent Thoelke, CEO,
Paradigm. "We're proud to help create more equitable access to
clinical trials for patients in Arkansas through our work with Highlands, as
well as in similar communities across the US. We imagine a world
where everyone can get the most advanced care possible, no matter
their geography."
Highlands works with Paradigm to evaluate the feasibility of new
clinical trials and screen patients for recruitment. This
partnership has helped the research team increase productivity and
efficiency. First, Paradigm securely integrates patient clinical
data from Highlands' EMR, as well as test results from all five of
Highlands' molecular testing vendors to streamline all aspects of
recruitment. Highlands also receives new phase I, II, and III
interventional therapeutic clinical trial opportunities through
Paradigm from pharmaceutical and biotechnology sponsors that are
pre-qualified and aligned with Highlands' local patient population,
capabilities, research portfolio, interests and objectives.
"Highlands has increased clinical trial patient enrollment by
45% over the last two years, while also reducing the burden on the
research department," said Adam
Torres, BSBA, BSN, RN, CCRP, Director of Research
Development, Highlands Oncology. "These accomplishments were
achieved through the deployment of industry leading best practices,
technology, and automations, including Paradigm, who has served as
an invaluable partner for our research program."
Read more details in the case study with Highlands Oncology.
About Highlands
Highlands Oncology provides comprehensive cancer care to
Northwest Arkansas and the
surrounding areas. They focus on offering and providing access to
all the resources you might need when faced with a cancer
diagnosis. Highlands prides itself on making world renowned cancer
care available to patients in Northwest
Arkansas so they are able to receive the care and treatment
they need close to the ones they love in the place they call
home.
About Paradigm
Paradigm is rebuilding the clinical research ecosystem by
creating a platform that enables equitable access to trials for all
patients, while enhancing trial efficiency and reducing the
barriers to participation for healthcare providers. Incubated by
ARCH Venture Partners and backed by leading healthcare and life
sciences investors, Paradigm aims to break down barriers across the
trial ecosystem through one seamless infrastructure implemented at
healthcare provider organizations, bringing potentially life-saving
therapies to patients faster.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/highlands-and-paradigm-improve-access-to-cancer-care-options-in-northwest-arkansas-increasing-clinical-trial-participation-by-45-302206205.html
SOURCE Paradigm Health, Inc.